222 related articles for article (PubMed ID: 16643847)
81. Low B and T lymphocyte attenuator expression on CD4+ T cells in the early stage of sepsis is associated with the severity and mortality of septic patients: a prospective cohort study.
Shao R; Li CS; Fang Y; Zhao L; Hang C
Crit Care; 2015 Aug; 19(1):308. PubMed ID: 26329820
[TBL] [Abstract][Full Text] [Related]
82. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
83. BTLA Expression and Function Are Impaired on SLE B Cells.
Wiedemann A; Lettau M; Weißenberg SY; Stefanski AL; Schrezenmeier EV; Rincon-Arevalo H; Reiter K; Alexander T; Hiepe F; Lino AC; Dörner T
Front Immunol; 2021; 12():667991. PubMed ID: 33968071
[TBL] [Abstract][Full Text] [Related]
84. Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells.
Owada T; Watanabe N; Oki M; Oya Y; Saito Y; Saito T; Iwamoto I; Murphy TL; Murphy KM; Nakajima H
J Leukoc Biol; 2010 Mar; 87(3):425-32. PubMed ID: 19892849
[TBL] [Abstract][Full Text] [Related]
85. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.
Gertner-Dardenne J; Fauriat C; Orlanducci F; Thibult ML; Pastor S; Fitzgibbon J; Bouabdallah R; Xerri L; Olive D
Blood; 2013 Aug; 122(6):922-31. PubMed ID: 23692853
[TBL] [Abstract][Full Text] [Related]
86. BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival.
Zhang J; Zhang H; Wang Z; Yang H; Chen H; Cheng H; Zhou J; Zheng M; Tan R; Gu M
Sci Rep; 2019 Aug; 9(1):12154. PubMed ID: 31434927
[TBL] [Abstract][Full Text] [Related]
87. Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.
Sawaf M; Fauny JD; Felten R; Sagez F; Gottenberg JE; Dumortier H; Monneaux F
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997289
[TBL] [Abstract][Full Text] [Related]
88. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator.
Oya Y; Watanabe N; Owada T; Oki M; Hirose K; Suto A; Kagami S; Nakajima H; Kishimoto T; Iwamoto I; Murphy TL; Murphy KM; Saito Y
Arthritis Rheum; 2008 Aug; 58(8):2498-510. PubMed ID: 18668554
[TBL] [Abstract][Full Text] [Related]
89. Roles of BTLA in Immunity and Immune Disorders.
Ning Z; Liu K; Xiong H
Front Immunol; 2021; 12():654960. PubMed ID: 33859648
[TBL] [Abstract][Full Text] [Related]
90. BTLA: a new inhibitory receptor with a B7-like ligand.
Carreno BM; Collins M
Trends Immunol; 2003 Oct; 24(10):524-7. PubMed ID: 14552835
[TBL] [Abstract][Full Text] [Related]
91. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.
Croft M
Trends Immunol; 2005 Jun; 26(6):292-4. PubMed ID: 15922943
[TBL] [Abstract][Full Text] [Related]
92. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.
Paulos CM; June CH
J Clin Invest; 2010 Jan; 120(1):76-80. PubMed ID: 20038807
[TBL] [Abstract][Full Text] [Related]
93. Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction.
Liu X; Alexiou M; Martin-Orozco N; Chung Y; Nurieva RI; Ma L; Tian Q; Kollias G; Lu S; Graf D; Dong C
J Immunol; 2009 Apr; 182(8):4516-20. PubMed ID: 19342624
[TBL] [Abstract][Full Text] [Related]
94. Age-related changes in the gene expression profile of antigen-specific mouse CD8+ T cells can be partially reversed by blockade of the BTLA/CD160 pathways during vaccination.
Dawany N; Parzych EM; Showe LC; Ertl HC
Aging (Albany NY); 2016 Nov; 8(12):3272-3297. PubMed ID: 27922818
[TBL] [Abstract][Full Text] [Related]
95. B and T lymphocyte attenuator restricts the protective immune response against experimental malaria.
Adler G; Steeg C; Pfeffer K; Murphy TL; Murphy KM; Langhorne J; Jacobs T
J Immunol; 2011 Nov; 187(10):5310-9. PubMed ID: 21998455
[TBL] [Abstract][Full Text] [Related]
96. B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients.
Shubin NJ; Monaghan SF; Heffernan DS; Chung CS; Ayala A
Crit Care; 2013 Nov; 17(6):R276. PubMed ID: 24289156
[TBL] [Abstract][Full Text] [Related]
97. A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex.
Axelsson S; Magnuson A; Lange A; Alshamari A; Hörnquist EH; Hultgren O
BMC Immunol; 2020 Mar; 21(1):14. PubMed ID: 32197584
[TBL] [Abstract][Full Text] [Related]
98. Generation of novel anti-BTLA monoclonal antibodies for in vivo use and their functional testing at near-physiological conditions.
Gurka S; Worbs S; Kroczek RA
Hybridoma (Larchmt); 2009 Dec; 28(6):405-14. PubMed ID: 20025499
[TBL] [Abstract][Full Text] [Related]
99. BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19
Chen YL; Lin HW; Chien CL; Lai YL; Sun WZ; Chen CA; Cheng WF
J Immunother Cancer; 2019 Nov; 7(1):313. PubMed ID: 31753019
[TBL] [Abstract][Full Text] [Related]
100. The inhibitory receptor BTLA controls γδ T cell homeostasis and inflammatory responses.
Bekiaris V; Šedý JR; Macauley MG; Rhode-Kurnow A; Ware CF
Immunity; 2013 Dec; 39(6):1082-1094. PubMed ID: 24315996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
